Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE) , sold 9,705 shares of common stock on September 4, 2026, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 weighted average sale price ($26.22). Maze Therapeutics is a clinical-stage biopharmaceutical company with a market cap of $1.50 billion, investing substantially in clinical development. The company's strategy centers on leveraging precision medicine approaches to develop targeted therapies for genetically defined kidney and metabolic diseases, positioning itself to address significant therapeutic gaps in rare disease treatment. Continue reading